STOCK TITAN

Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Silexion Therapeutics Corp received an updated ownership report from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on June 30, 2026, the reporting persons state they may be deemed to have beneficial ownership of no Ordinary Shares, representing 0.0% of the outstanding class. They hold two warrants for 32,500 and 38,920 Ordinary Shares, respectively, but these are not exercisable until stockholder approval of the underlying share issuances and each is subject to a 9.99% beneficial ownership blocker. Without these blocker provisions and assuming exercisability, they indicate potential beneficial ownership of 71,420 Ordinary Shares, yet currently report no voting or dispositive power over any shares.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 0 Ordinary Shares As of close of business on June 30, 2026
Percent of class 0.0% Reported beneficial ownership of Silexion Ordinary Shares
Intracoastal Warrant 1 32,500 Ordinary Shares Ordinary Shares issuable upon exercise, subject to stockholder approval and blocker
Intracoastal Warrant 2 38,920 Ordinary Shares Ordinary Shares issuable upon exercise, subject to stockholder approval and blocker
Potential warrant coverage 71,420 Ordinary Shares Total shares underlying both warrants absent blocker and exercisability limits
Beneficial ownership blocker 9.99% Maximum beneficial ownership allowed upon warrant exercise
beneficial ownership financial
"each of the Reporting Persons may have been deemed to have beneficial ownership of no Ordinary Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
blocker provision financial
"Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise"
beneficial ownership of more than 9.99% financial
"any of the holder's affiliates, of more than 9.99% of the Ordinary Shares"
warrant financial
"32,500 Ordinary Shares issuable upon exercise of a warrant held by Intracoastal"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
Ordinary Shares financial
"Ordinary shares, par value $0.135 per share"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What ownership in Silexion Therapeutics Corp (SLXN) do the reporting persons disclose?

They report beneficial ownership of no Ordinary Shares of Silexion Therapeutics Corp, representing 0.0% of the class as of June 30, 2026, with no sole or shared voting or dispositive power reported.

Why are the SLXN warrants excluded from current beneficial ownership?

They are excluded because each warrant is not exercisable until the effective date of stockholder approval for the underlying share issuances and includes a 9.99% beneficial ownership blocker, limiting exercisability above that threshold.

What potential SLXN ownership is referenced if blockers and conditions did not apply?

Without the blocker provisions and assuming both warrants were exercisable, the reporting persons state they may have been deemed to beneficially own 71,420 Ordinary Shares, though they currently report 0.0% of the class.

What is the reported percentage of class owned in Silexion Therapeutics (SLXN)?

The filing states the reporting persons’ beneficial ownership is 0.0% of Silexion’s Ordinary Shares, and confirms they have 0 sole or shared power to vote or dispose of any shares as of June 30, 2026.

What is the beneficial ownership limitation applied to the SLXN warrants?

Each Intracoastal warrant includes a 9.99% beneficial ownership blocker, preventing exercise to the extent it would cause the holder and certain related parties to own more than 9.99% of Silexion’s Ordinary Shares.





G1281K114

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Mitchell P. Kopin
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin
Date:08/13/2026
Daniel B. Asher
Signature:/s/ Daniel B. Asher
Name/Title:Daniel B. Asher
Date:08/13/2026
Intracoastal Capital LLC
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin, Manager
Date:08/13/2026